Emcutix Biopharmaceuticals, a wholly owned subsidiary of Emcure Pharmaceuticals, has launched its new AquaOat range, powered by NanoCeLiD technology. The innovative formulation combines advanced nanotechnology and lipid chemistry to enhance ceramide penetration into the deeper layers of the skin while delivering the soothing benefits of colloidal oatmeal—setting it apart from conventional skincare solutions.
The AquaOat range is specifically developed to address the unmet needs of patients suffering from eczema and related conditions such as atopic dermatitis, contact dermatitis, and urticaria.
With dermatitis and chronic dry skin becoming increasingly common across India, affecting both children and adults, effective skin barrier restoration has become a key focus in dermatological care. Although ceramide-based formulations are known for their skin-repairing properties, their limited penetration due to molecular size and solubility often reduces their long-term efficacy.
NanoCeLiD technology overcomes these challenges by using nano-sized ceramide encapsulated in lipid, improving both skin absorption and bioavailability. By mimicking skin-identical lipids with superior biocompatibility, AquaOat offers sustained relief and promotes effective restoration of the skin barrier.